Prefibrotic/Early Primary Myelofibrosis Clinical Trials in Annecy

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms